Key result
Surgical removal of visceral adipose tissue (omentectomy) offers no benefit in improving systemic inflammation and metabolic control, while the metabolic benefits of subcutaneous fat removal remain inconclusive.
Why the study?
Does surgical reduction of visceral or subcutaneous fat improve features of the metabolic syndrome in obese patients?
Does surgical reduction of visceral or subcutaneous fat improve features of the metabolic syndrome in obese patients?
Answers are grounded in this paper and cite their sources.
Current evidence suggests that surgical removal of visceral fat (omentectomy) does not improve metabolic syndrome, challenging the hypothesis that visceral fat removal alone is an effective treatment for obesity-related metabolic disease.
Obesity results in both health and financial tolls for individuals and society. Despite the great efforts to increase awareness, the obesity epidemic continues at an alarming rate. Subcutaneous fat represents 85% of the fat mass in obese patients, while intra-abdominal fat, including both visceral and retroperitoneal adipose, represent about 15%. Both subcutaneous and visceral fat have a negative effect on individual health and promote metabolic diseases. Logic would thus suggest that adipose tissue removal by liposuction and/or visceral tissue removal could effect an improvement in metabolic diseases such as Type 2 diabetes?
No takes yet. Share an insight, caveat, or question.
A 2016 study conducted a review in Obesity and Metabolic Syndrome. Surgical reduction of visceral and subcutaneous fat (Liposuction and Omentectomy) was evaluated. Surgical removal of visceral adipose tissue (omentectomy) offers no benefit in improving systemic inflammation and metabolic control, while the metabolic benefits of subcutaneous fat removal remain inconclusive.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: